Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec:26 Suppl 1:35-40.
doi: 10.1111/1744-9987.13857. Epub 2022 Dec 5.

Beyond cholesterol-pleiotropic effects of lipoprotein apheresis

Affiliations

Beyond cholesterol-pleiotropic effects of lipoprotein apheresis

Volker J J Schettler et al. Ther Apher Dial. 2022 Dec.

Abstract

Cardiovascular disease is a leading cause of mortality worldwide, which is caused mainly by atherosclerosis, a chronic inflammatory disease of blood vessels. Therefore, atherosclerosis represents a complex disorder, which induces damage or imbalance on different levels: for example, genes, cytokines, lipoproteins, cells, vessels, and organs. Lipoprotein apheresis (LA) is a well-established extracorporeal treatment of severe hyperlipoproteinemia. In addition, LA may have simultaneously crucial effects on many other atherogenic factors during the treatments, for example, as vascular inflammation, rheology, mobilization of adult stem cells and gene expressions in blood or endothelial cells, which will be discussed in this short review. In addition, stable microRNAs besides tissues also appear in extracellular compartments, for example, vessels, involved in atherosclerotic processes, were found to be reduced by LA treatments. In summary, LA represents a complex therapeutic procedure, that provides an ideal tool for the treatment of complex disorders such as atherosclerosis.

Keywords: atherosclerosis; exosomes; inflammation; lipoprotein apheresis; pleiotropic effects.

PubMed Disclaimer

References

REFERENCES

    1. Spitthover R, Roseler T, Julius U, Heigl F, Schettler VJJ, Kühn R, et al. Real-world study: escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. J Clin Apher. 2019;34:423-33. https://doi.org/10.1002/jca.21695
    1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-88. https://doi.org/10.1093/eurheartj/ehz455
    1. Reijman MD, Kusters DM, Wiegman A. Advances in familial hypercholesterolaemia in children. Lancet Child Adolesc Health. 2021;5:652-61. https://doi.org/10.1016/S2352-4642(21)00095-X
    1. Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl. 2013;14:19-27. https://doi.org/10.1016/j.atherosclerosissup.2012.10.021
    1. Borberg H. Results of an open, longitudinal multicenter LDL-apheresis trial. Transfus Sci. 1999;20:83-94. https://doi.org/10.1016/s0955-3886(98)00097-6

LinkOut - more resources